ReviewOncogene2007
Hematopoietic cytokine receptor signaling.
Review in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 250 citations in OpenAlex.
- Trial
- Mechanisms of fibrotic tissue remodelling: insights from systemic sclerosis.Nature reviews. Rheumatology · 2026Review
- IL-7 promotes naïve T cell motility to enable T cell scanning of dendritic cells in the LN.Cytokine · 2026Article
- Article
- Enzyme Is the Name-Adapter Is the Game.Cells · 2024Review
- Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study.Therapeutic advances in hematology · 2024Article
- BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors.Blood advances · 2022Article
- Cytokine pathway variants modulate platelet production: IFNA16 is a thrombocytosis susceptibility locus in humans.Blood advances · 2022Article
- JAK/STAT: Why choose a classical or an alternative pathway when you can have both?Journal of cellular and molecular medicine · 2022Review
- Critical roles of PTPN family members regulated by non-coding RNAs in tumorigenesis and immunotherapy.Frontiers in oncology · 2022Review
- Evolution of γ chain cytokines: Mechanisms, methods and applications.Computational and structural biotechnology journal · 2022Review
- Therapeutic targeting of the inflammasome in myeloid malignancies.Blood cancer journal · 2021Review
- Mechanism of mutant calreticulin-mediated activation of the thrombopoietin receptor in cancers.The Journal of cell biology · 2021Article
- Elevated IL-15 concentrations in the sarcoidosis lung are independent of granuloma burden and disease phenotypes.American journal of physiology. Lung cellular and molecular physiology · 2021Article
- Article
- Inflammasome Activation in Myeloid Malignancies-Friend or Foe?Frontiers in cell and developmental biology · 2021Review
- Stem cell quiescence and its clinical relevance.World journal of stem cells · 2020Review
- ARHGEF4 Regulates an Essential Oncogenic Program in t(12;21)-Associated Acute Lymphoblastic Leukemia.HemaSphere · 2020Article
- Orchestration of signaling by structural disorder in class 1 cytokine receptors.Cell communication and signaling : CCS · 2020Article
- Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.Cancers · 2020Review
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are mediated by cytokines and their receptors. Proper culmination of these diverse pathways forms the basis for an orderly generation of different cell types. Recent studies conducted over the past 10-15 years have revealed that hematopoietic cytokine receptor signaling is largely mediated by a family of tyrosine kinases termed Janus kinases (JAKs) and their downstream transcription factors termed STATs (signal transducers and activators of transcription). Aberration in these pathways, such as that caused by the recently identified JAK2V617F mutation, is an underlying cause for diseases such as leukemias and other myeloproliferative disorders. This recent discovery, when coupled with the fact that STATs are activated by oncoproteins such as BCR-ABL, underscores the importance of the JAK-STAT pathway in both normal cellular development and disease states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.